



SPARC/Sec/SE/2026-27/05

April 30, 2026

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Symbol: SPARC

Scrip Code: 532872

Dear Sir/ Madam,

Sub: Press Release - SPARC Announces Sale of Priority Review Voucher for US \$ 195 million (One Hundred and Ninety-Five Million Dollars)

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Press Release on the above mentioned subject, which we shall be releasing after sending this letter to you.

The disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR") read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 for the Sale of Priority Review Voucher is provided in **Annexure A**.

This is for your information and dissemination purpose.

Yours faithfully,

For **Sun Pharma Advanced Research Company Ltd.**

Kajal Damania
Company Secretary and Compliance Officer

Annexure A

Disclosure under Regulation 30 of SEBI LODR of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Sr. No	Particulars	Details
1	Purpose of entering into the agreement	Sale of Priority Review Voucher ("PRV")
2	Size of agreement	US \$195 million (One Hundred and Ninety-Five Million Dollars)
3	Shareholding, if any, in the entity with whom the agreement is executed	Nil
4	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc	NA
5	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	No
6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	No
7	In case of issuance of shares to the parties, details of issue price, class of shares issued	NA
8	In case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis.	NA
9	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc	NA

10	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s)	NA
	a) name of parties to the agreement;	
	b) nature of the agreement;	
	c) date of execution of the agreement;	
	d) details of amendment and impact thereof or reasons of termination and impact thereof.	



FOR IMMEDIATE RELEASE

SPARC Announces Sale of Priority Review Voucher for US \$195 million

MUMBAI, April 30, 2026, Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced that SPARC has entered into a definitive asset purchase agreement to sell its Rare Paediatric Disease Priority Review Voucher ("PRV") for US \$195 million upon the closing of the transaction.

PRV was granted by the U.S. Food and Drug Administration (FDA) for the approval of Sezaby® indicated for the treatment of neonatal seizures.

"The sale of the PRV will enable us to accelerate the development of our pipeline assets and strengthen our external innovation strategy, which has already delivered multiple additions to our portfolio," said Anil Raghavan, CEO of SPARC.

The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act.

Stifel acted as the exclusive financial advisor to SPARC with respect to this transaction.

About Sezaby®:

SEZABY® is a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium powder for injection. It was approved by FDA for the treatment of neonatal seizures.

About SPARC (CIN: L73100GJ2006PLC047837):

Sun Pharma Advanced Research Company Ltd. ('SPARC') is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. SPARC consistently aims to lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world. More information about the company can be found at www.sparc.life.

Media Contacts:

Jaydeep Issrani
Tel +91 22 66455645, Extn: 5787
Tel Direct +91 22 6645 5787
Mobile +91-9820216916
E mail jaydeep.issrani@sparcmail.com

Sun Pharma Advanced Research Company Ltd.

17/B, Mahal Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India.
Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: www.sparc.life

Registered office : Plot no. 5&6/1, Savli GIDC Estate, Manjusar 391775, District: Vadodara, Gujarat, India.